Fecal Microbiota Transplant (FMT)

The transfer of processed stool from a healthy donor into a recipient's gastrointestinal tract to restore a disrupted microbial community. FMT is the most direct form of microbiome intervention -- replacing the entire community rather than supplementing individual strains (probiotics) or feeding existing commensals (prebiotics). It represents community-level ecological restoration.

Mechanism

FMT introduces a complex, intact microbial ecosystem including bacteria, archaea, fungi (mycobiome), bacteriophages, and their metabolites. Proposed mechanisms of action:
1. Colonization resistance restoration: Donor commensals outcompete pathogens for niches and nutrients.
2. SCFA production recovery: Donor butyrate/propionate producers re-establish fermentative metabolism and colonocyte energy supply.
3. Bile acid metabolism normalization: Donor bacteria restore secondary bile acid production, which inhibits C. difficile sporulation.
4. Immune recalibration: Restored SCFA and indoles production rebalances Treg/Th17 and reduces inflammation.
5. Barrier repair: Recovered butyrate production strengthens tight junctions and restores hypoxic colonic environment.

Clinical Evidence by Disease

C. difficile Infection (Gold Standard)

- FMT cures recurrent C. difficile in ~90% of cases -- far superior to antibiotics alone.
- FDA-approved live biotherapeutic products (REBYOTA, VOWST) now available.
- Mechanism primarily through restored colonization resistance and secondary bile acid metabolism.

IBD (Mixed Results)

- Ulcerative colitis: Multiple RCTs show induction of remission in 25-35% of patients (vs. 5-10% placebo), but durability and optimal protocols remain uncertain.
- Crohn's disease: Preliminary evidence; timing of repeat FMT may be critical (e.g., second FMT within 3 weeks showed greater mucosal improvement).
- Challenge: IBD involves immune dysregulation beyond what microbiome restoration alone can correct.

Multiple Sclerosis (Pilot Data)

- Mouse models: FMT from MS-twin-derived microbiota increased autoimmune incidence; FMT from healthy donors showed protective immunoregulatory activity [martinelli 2022 gut oriented interventions ms].
- Sutterella reduction identified as a key change in MS-associated FMT.
- Human data remain very limited; larger trials needed.

Cardiovascular Disease / Hypertension

- FMT from atherosclerotic mice induces atherosclerosis in recipient mice, demonstrating causal microbial contribution [herrema 2020 microbiome cardiovascular disease ascvd].
- FMT as an innovative therapeutic approach for managing CVD is under active investigation [luqman 2024 intestinal microbiome cvd intervention].

Autism Spectrum Disorder (Open-Label)

- Open-label FMT trial in ASD children reduced levels of p-cresol, 4-hydroxyphenylacetate, and indole; modified Prevotella, bifidobacterium, and Desulfovibrio abundances [zheng 2021 bacterial aromatic amino acids asd].
- GI symptoms and behavioral measures improved; effects persisted at 2-year follow-up in extended observations.
- Controlled trials are needed to confirm efficacy.

Other Applications Under Investigation

- Metabolic syndrome/obesity: FMT from lean donors to obese recipients temporarily improved insulin sensitivity in some trials.
- Hepatic encephalopathy: FMT reduced hospitalizations in cirrhotic patients.
- Graft-versus-host disease: FMT showing promise for steroid-refractory GI GVHD.

Metal Angle

FMT may restore the metal-handling capacity of the microbiome disrupted by heavy metal exposure:
- Biosorption capacity: Healthy donor microbiota includes metal-binding species (Lactobacillus, Bifidobacterium) that sequester Pb, Cd, and Hg in the gut lumen.
- Barrier repair: Restored SCFA production reduces paracellular metal absorption through healed tight junctions.
- Competitive exclusion: Donor commensals displace metal-tolerant pathobionts (Enterobacteriaceae) that thrive in metal-contaminated, inflamed environments.
- Detoxification enzymes: Donor bacteria may contribute arsenic methyltransferases (arsM), mercury demethylases (merB), and other biotransformation enzymes.

Limitations and Risks

- Donor screening: Risk of transmitting infections, antibiotic-resistant organisms, or unfavorable metabolic phenotypes.
- Durability: Engraftment is often incomplete; recipient diet and environment may select against donor species.
- Standardization: No consensus on preparation (fresh vs. frozen, capsule vs. colonoscopy), dosing, or donor selection criteria.
- Regulatory: Classified as a biological product; access varies by jurisdiction.